#Obesity medicine
Chronic weight management as a clinical specialty.
PNPHO nanocarrier for nasal semaglutide
A thermoresponsive PNPHO nanocarrier encapsulated semaglutide at 89% efficiency and improved glucose tolerance in animals. The research is preclinical.
PNPHO nanocarrier for nasal semaglutide
A thermoresponsive PNPHO nanocarrier encapsulated semaglutide at 89% efficiency and improved glucose tolerance in animals. The research is preclinical.
Semaglutide and CRP in obesity: 2026 data
A 2026 meta-analysis of nine trials found semaglutide cut body weight 12% and C-reactive protein 41% versus placebo in non-diabetic adults with obesity.
GLP-1 drugs in lipedema: survey evidence
A 2026 Obesity Pillars survey collected self-reported outcomes from people with lipedema on GLP-1 or GLP-1/GIP drugs. Patient data, but no controlled trial.
SURMOUNT-1: glycemia markers and T2D risk
A 2026 post hoc SURMOUNT-1 analysis tested three glycemia markers in prediabetes. OGTT one-hour glucose caught 83% of T2D progressors. HbA1c alone missed 53%.
GLP-1 maintenance dosing: what trials show
Approved GLP-1 labels define a maximum dose, not a separate maintenance phase. SURMOUNT-4 and STEP-4 show what happens when you stop.
US employers pulling GLP-1 coverage in 2027
About 14% of large US employers have dropped or plan to drop GLP-1 obesity drug coverage in 2027, as pharmacy costs hit 25% of total healthcare spend.
Zepbound cost savings; ivonescimab biliary
A matched cohort study finds Zepbound users over 55 spent up to $607 less per month by month 12; ivonescimab shows a survival benefit in biliary cancer.
Lilly's Medicare GLP-1 push: what changed
Lilly's 'A Life Covered' campaign targets the Medicare Part D exclusion for obesity drugs. Here is what the campaign asks for and what has already shifted.
Lilly obesity campaign and GLP-1 access
Lilly's new obesity campaign brings older adults into view as CMS prepares a limited Medicare GLP-1 access demonstration.
Semaglutide: body composition at 12 months
A 2026 Obesity Facts study followed 83 adults for 12 months. Semaglutide cut more weight, improved muscle quality scores, and preserved handgrip strength.
Tirzepatide weight loss outcomes in PCOS
A UK real-world study found similar 10-month tirzepatide weight loss in women with self-reported PCOS and women without PCOS.